| 1 | Potocki-shaffer syndrome | Enrichment | ALX4, EXT2, PHF21A | 6.60 |
| 2 | Exostoses, multiple, type i | Enrichment | EXT1, EXT2 | 4.79 |
| 3 | Neural tube defects | Enrichment | ITGB1, VANGL1 | 2.91 |
| 4 | Neonatal adrenoleukodystrophy | Enrichment | PEX16, PEX3 | 2.91 |
| 5 | Peroxisome biogenesis disorder 1b | Enrichment | PEX16, PEX3 | 2.79 |
| 6 | Zellweger syndrome | Enrichment | PEX16, PEX3 | 2.79 |
| 7 | Hepatoblastoma | Enrichment | EXT2, TP53 | 2.49 |
| 8 | Holoprosencephaly 3 | Enrichment | SHH | 2.39 |
| 9 | Pallister-hall syndrome | Enrichment | GLI3 | 2.39 |
| 10 | Greig cephalopolysyndactyly syndrome | Enrichment | GLI3 | 2.39 |
| 11 | Macular dystrophy, corneal | Enrichment | CHST6 | 2.39 |
| 12 | Chondrosarcoma | Enrichment | EXT1 | 2.39 |
| 13 | Hyperopia, high | Enrichment | NRXN1 | 2.39 |
| 14 | Congenital disorder of glycosylation, type iic | Enrichment | SLC35C1 | 2.39 |
| 15 | Polydactyly, preaxial iv | Enrichment | GLI3 | 2.39 |
| 16 | Peroxisome biogenesis disorder 10a | Enrichment | PEX3 | 2.39 |
| 17 | Raph blood group system | Enrichment | CD151 | 2.39 |
| 18 | Microphthalmia/coloboma 5 | Enrichment | SHH | 2.39 |
| 19 | Muscular dystrophy-dystroglycanopathy , type a, 13 | Enrichment | B4GAT1 | 2.39 |
| 20 | Peroxisome biogenesis disorder 8a | Enrichment | PEX16 | 2.39 |
| 21 | Frontonasal dysplasia 2 | Enrichment | ALX4 | 2.39 |
| 22 | Wilms tumor 6 | Enrichment | REST | 2.39 |
| 23 | Ectodermal dysplasia 17 with or without limb malformations | Enrichment | LEF1 | 2.39 |
| 24 | Peroxisome biogenesis disorder 10b | Enrichment | PEX3 | 2.39 |
| 25 | Intellectual developmental disorder, autosomal recessive 46 | Enrichment | NDST1 | 2.39 |
| 26 | Bone marrow failure syndrome 5 | Enrichment | TP53 | 2.39 |
| 27 | Okt4 epitope deficiency | Enrichment | CD4 | 2.39 |
| 28 | Pitt-hopkins-like syndrome 2 | Enrichment | NRXN1 | 2.39 |
| 29 | Papilloma of choroid plexus | Enrichment | TP53 | 2.39 |
| 30 | Basal cell carcinoma 7 | Enrichment | TP53 | 2.39 |
| 31 | Anaplastic thyroid carcinoma | Enrichment | TP53 | 2.39 |
| 32 | Craniosynostosis 5 | Enrichment | ALX4 | 2.39 |
| 33 | Parietal foramina 2 | Enrichment | ALX4 | 2.39 |
| 34 | Epidermolysis bullosa simplex 7, with nephropathy and deafness | Enrichment | CD151 | 2.39 |
| 35 | Deafness, autosomal dominant 27 | Enrichment | REST | 2.39 |
| 36 | Intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures | Enrichment | PHF21A | 2.39 |
| 37 | Graham little-piccardi-lassueur syndrome | Enrichment | HLA-DRA | 2.39 |
| 38 | Chromosome 2p16.3 deletion syndrome | Enrichment | NRXN1 | 2.39 |
| 39 | Peroxisome biogenesis disorder 8b | Enrichment | PEX16 | 2.39 |
| 40 | Immunodeficiency, common variable, 3 | Enrichment | CD19 | 2.39 |
| 41 | Immunodeficiency, common variable, 5 | Enrichment | MS4A1 | 2.39 |
| 42 | Ductal carcinoma in situ | Enrichment | TP53 | 2.39 |
| 43 | Fibromatosis, gingival, 5 | Enrichment | REST | 2.39 |
| 44 | Hereditary multiple osteochondromas | Enrichment | EXT1 | 2.39 |
| 45 | Exostosis | Enrichment | EXT1 | 2.39 |
| 46 | Immunodeficiency 79 | Enrichment | CD4 | 2.39 |
| 47 | Nrxn1-related severe neurodevelopmental disorder-motor stereotypies-chronic constipation-sleep-wake cycle disturbance | Enrichment | NRXN1 | 2.39 |
| 48 | Thyroid gland undifferentiated carcinoma | Enrichment | TP53 | 2.39 |
| 49 | Small-cell carcinoma of the ovary of hypercalcemic type | Enrichment | TP53 | 2.39 |
| 50 | Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype | Enrichment | TP53 | 2.39 |
| 51 | Choroid plexus cancer | Enrichment | TP53 | 2.39 |
| 52 | Autosomal recessive ataxia due to pex16 deficiency | Enrichment | PEX16 | 2.39 |
| 53 | Hereditary multiple exostoses | Enrichment | EXT1 | 2.39 |
| 54 | Pleomorphic xanthoastrocytoma | Enrichment | TP53 | 2.39 |
| 55 | Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome | Enrichment | SHH | 2.39 |
| 56 | Ovarian cancer | Enrichment | EXT1, EXT2, TP53 | 2.10 |
| 57 | Ectrodactyly and ectodermal dysplasia without cleft lip/palate | Enrichment | LEF1 | 2.09 |
| 58 | Leukocyte adhesion deficiency, type i | Enrichment | ITGB2 | 2.09 |
| 59 | Exostoses, multiple, type ii | Enrichment | EXT2 | 2.09 |
| 60 | Fibromatosis, gingival, 1 | Enrichment | REST | 2.09 |
| 61 | Adrenocortical carcinoma, hereditary | Enrichment | TP53 | 2.09 |
| 62 | Cervical cancer | Enrichment | TP53 | 2.09 |
| 63 | Leukocyte adhesion deficiency, type iii | Enrichment | ITGB2 | 2.09 |
| 64 | Solitary median maxillary central incisor | Enrichment | SHH | 2.09 |
| 65 | Lymphoma, hodgkin, classic | Enrichment | TP53 | 2.09 |
| 66 | Tibial hemimelia | Enrichment | GLI3 | 2.09 |
| 67 | Epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome | Enrichment | ITGA3 | 2.09 |
| 68 | Parietal foramina | Enrichment | ALX4 | 2.09 |
| 69 | Split hand-foot malformation | Enrichment | LEF1 | 2.09 |
| 70 | Synpolydactyly | Enrichment | GLI3 | 2.09 |
| 71 | Seizures, scoliosis, and macrocephaly/microcephaly syndrome | Enrichment | EXT2 | 2.09 |
| 72 | Congenital fibrosarcoma | Enrichment | TP53 | 2.09 |
| 73 | Li-fraumeni syndrome 1 | Enrichment | TP53 | 2.09 |
| 74 | Sarcoma | Enrichment | TP53 | 2.09 |
| 75 | Cervix carcinoma | Enrichment | TP53 | 2.09 |
| 76 | Hodgkin's lymphoma | Enrichment | TP53 | 2.09 |
| 77 | Common variable immunodeficiency phenotype due to cd19/cd81 deficiency | Enrichment | CD19 | 2.09 |
| 78 | Postaxial polydactyly type b | Enrichment | GLI3 | 2.09 |
| 79 | Non-syndromic sagittal craniosynostosis | Enrichment | ALX4 | 2.09 |
| 80 | Isolated radial hemimelia | Enrichment | SHH | 2.09 |
| 81 | Pleomorphic rhabdomyosarcoma | Enrichment | TP53 | 2.09 |
| 82 | Acrocallosal syndrome | Enrichment | GLI3 | 1.92 |
| 83 | Syndactyly, type iv | Enrichment | SHH | 1.92 |
| 84 | Aarskog-scott syndrome | Enrichment | GLI3 | 1.92 |
| 85 | Osteogenic sarcoma | Enrichment | TP53 | 1.92 |
| 86 | Nasopharyngeal carcinoma | Enrichment | TP53 | 1.92 |
| 87 | Epidermolysis bullosa, junctional 6, with pyloric atresia | Enrichment | ITGA6 | 1.92 |
| 88 | Umbilical hernia | Enrichment | GLI3 | 1.92 |
| 89 | Atypical teratoid rhabdoid tumor | Enrichment | TP53 | 1.92 |
| 90 | Anaplastic astrocytoma | Enrichment | TP53 | 1.92 |
| 91 | Hypoplastic or aplastic tibia with polydactyly | Enrichment | SHH | 1.92 |
| 92 | Squamous cell carcinoma | Enrichment | TP53 | 1.92 |
| 93 | Adenocarcinoma | Enrichment | TP53 | 1.92 |
| 94 | Bone osteosarcoma | Enrichment | TP53 | 1.92 |
| 95 | Trichorhinophalangeal syndrome, type ii | Enrichment | EXT1 | 1.79 |
| 96 | Polydactyly, preaxial ii | Enrichment | SHH | 1.79 |
| 97 | Small cell cancer of the lung | Enrichment | TP53 | 1.79 |
| 98 | Schizencephaly | Enrichment | SHH | 1.79 |
| 99 | Sacral defect with anterior meningocele | Enrichment | VANGL1 | 1.79 |
| 100 | Thyroid cancer, nonmedullary, 1 | Enrichment | TP53 | 1.79 |
| 101 | Retinitis pigmentosa 26 | Enrichment | ITGA4 | 1.79 |
| 102 | Lung sarcomatoid carcinoma | Enrichment | TP53 | 1.79 |
| 103 | Embryonal rhabdomyosarcoma | Enrichment | TP53 | 1.79 |
| 104 | Gingival fibromatosis | Enrichment | REST | 1.79 |
| 105 | Muscular dystrophy-dystroglycanopathy , type a, 1 | Enrichment | B4GAT1 | 1.70 |
| 106 | Rhabdomyosarcoma 2 | Enrichment | TP53 | 1.70 |
| 107 | Lymphoma | Enrichment | TP53 | 1.70 |
| 108 | Epidermolysis bullosa | Enrichment | ITGA6 | 1.70 |
| 109 | Acute megakaryocytic leukemia | Enrichment | TP53 | 1.70 |
| 110 | Li-fraumeni syndrome | Enrichment | TP53 | 1.62 |
| 111 | Peroxisome biogenesis disorder 1a | Enrichment | PEX3 | 1.62 |
| 112 | Split-hand/foot malformation 1 | Enrichment | LEF1 | 1.62 |
| 113 | Epidermolysis bullosa, junctional 5b, with pyloric atresia | Enrichment | ITGA6 | 1.62 |
| 114 | Adrenocortical carcinoma | Enrichment | TP53 | 1.62 |
| 115 | Breast adenocarcinoma | Enrichment | TP53 | 1.62 |
| 116 | Esophageal cancer | Enrichment | TP53 | 1.55 |
| 117 | Fundus albipunctatus | Enrichment | CD63 | 1.55 |
| 118 | Squamous cell carcinoma, head and neck | Enrichment | TP53 | 1.55 |
| 119 | Essential thrombocythemia | Enrichment | TP53 | 1.55 |
| 120 | Gallbladder cancer | Enrichment | TP53 | 1.55 |
| 121 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Enrichment | TP53 | 1.55 |
| 122 | Glioma susceptibility 1 | Enrichment | TP53 | 1.50 |
| 123 | Lymphoma, non-hodgkin, familial | Enrichment | TP53 | 1.50 |
| 124 | Autism | Enrichment | NRXN1, SHH | 1.46 |
| 125 | Adult hepatocellular carcinoma | Enrichment | TP53 | 1.44 |
| 126 | Junctional epidermolysis bullosa | Enrichment | ITGA6 | 1.44 |
| 127 | Primary hyperaldosteronism | Enrichment | TP53 | 1.44 |
| 128 | Leukemia, chronic lymphocytic | Enrichment | TP53 | 1.40 |
| 129 | Familial colorectal cancer | Enrichment | TP53 | 1.40 |
| 130 | Myelodysplastic syndrome | Enrichment | TP53 | 1.36 |
| 131 | Septooptic dysplasia | Enrichment | SHH | 1.32 |
| 132 | Lip and oral cavity carcinoma | Enrichment | TP53 | 1.32 |
| 133 | Diaphragmatic hernia, congenital | Enrichment | GLI3 | 1.29 |
| 134 | Lung cancer susceptibility 3 | Enrichment | TP53 | 1.26 |
| 135 | Walker-warburg syndrome | Enrichment | B4GAT1 | 1.26 |
| 136 | Isolated macular dystrophy | Enrichment | ITGA4 | 1.26 |
| 137 | Polydactyly, postaxial, type a1 | Enrichment | GLI3 | 1.23 |
| 138 | Wilms tumor 1 | Enrichment | REST | 1.23 |
| 139 | Septopreoptic holoprosencephaly | Enrichment | SHH | 1.23 |
| 140 | Midline interhemispheric variant of holoprosencephaly | Enrichment | SHH | 1.23 |
| 141 | Rhabdomyosarcoma | Enrichment | TP53 | 1.20 |
| 142 | Gliosarcoma | Enrichment | TP53 | 1.20 |
| 143 | Microform holoprosencephaly | Enrichment | SHH | 1.20 |
| 144 | Lobar holoprosencephaly | Enrichment | SHH | 1.20 |
| 145 | Giant cell glioblastoma | Enrichment | TP53 | 1.18 |
| 146 | Alobar holoprosencephaly | Enrichment | SHH | 1.18 |
| 147 | Semilobar holoprosencephaly | Enrichment | SHH | 1.15 |
| 148 | Diffuse large b-cell lymphoma | Enrichment | TP53 | 1.13 |
| 149 | Macs syndrome | Enrichment | SHH | 1.11 |
| 150 | Craniosynostosis | Enrichment | GLI3 | 1.11 |
| 151 | Hepatocellular carcinoma | Enrichment | TP53 | 1.07 |
| 152 | Diamond-blackfan anemia 1 | Enrichment | TP53 | 1.05 |
| 153 | Congenital stationary night blindness | Enrichment | CD63 | 1.05 |
| 154 | Pancreatic cancer | Enrichment | TP53 | 1.01 |
| 155 | Inherited cancer-predisposing syndrome | Enrichment | EXT2, TP53 | 1.00 |
| 156 | Bladder cancer | Enrichment | TP53 | 0.95 |
| 157 | Hirschsprung disease 1 | Enrichment | GLI3 | 0.95 |
| 158 | Prostate cancer | Enrichment | TP53 | 0.95 |
| 159 | Diamond-blackfan anemia | Enrichment | TP53 | 0.87 |
| 160 | Leukemia, acute myeloid | Enrichment | TP53 | 0.82 |
| 161 | Type 2 diabetes mellitus | Enrichment | MAPK8IP1 | 0.80 |
| 162 | Gastric cancer | Enrichment | TP53 | 0.79 |
| 163 | Nephrotic syndrome | Enrichment | ITGA3 | 0.79 |
| 164 | Hereditary breast carcinoma | Enrichment | TP53 | 0.79 |
| 165 | Body mass index quantitative trait locus 11 | Enrichment | NRXN1 | 0.73 |
| 166 | Rare autosomal dominant non-syndromic sensorineural deafness type dfna | Enrichment | REST | 0.72 |
| 167 | Hereditary breast ovarian cancer syndrome | Enrichment | TP53 | 0.70 |
| 168 | Myeloma, multiple | Enrichment | TP53 | 0.69 |
| 169 | Autosomal recessive non-syndromic intellectual disability | Enrichment | NDST1 | 0.68 |
| 170 | Schizophrenia | Enrichment | NRXN1 | 0.67 |
| 171 | Cone-rod dystrophy 2 | Enrichment | ITGA4 | 0.62 |
| 172 | Breast cancer | Enrichment | TP53 | 0.58 |
| 173 | Colorectal cancer | Enrichment | TP53 | 0.52 |
| 174 | Hereditary retinal dystrophy | Enrichment | CD63, ITGA4 | 0.48 |
| 175 | Fundus dystrophy | Enrichment | CD63, ITGA4 | 0.48 |
| 176 | Autism spectrum disorder | Enrichment | NRXN1 | 0.44 |